Navigation Links
China Nepstar Chain Drugstore Reports Third Quarter 2013 Financial Results

SHENZHEN, China, Nov. 26, 2013 /PRNewswire-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the third quarter ended September 30, 2013.

Financial HighlightsFor the quarter ended September 30, 2013:

  • Same store sales increased by 10.5% compared with the third quarter of 2012
  • Revenue grew by 7.7% compared with the third quarter of 2012
  • Net loss was RMB4.7 million
  • Net cash-flow from operating activities was RMB10.6 million (US$1.7 million), compared to RMB0.05 million in the third quarter of 2012
  • Mr. Fuxiang Zhang, Chief Executive Officer of Nepstar, commented, "We are pleased to report that our strategy of strong promotional activities and marketing campaigns resulted in continued momentum in revenue growth. During the third quarter, daily store traffic increased by 11 visits and same store sales grew by 10.5% from the same quarter in 2012. Our higher sales garnered attention internally among store staff, as well as externally from our suppliers who have shown their support. We believe that we are well positioned for the recovery of the retail pharmacy industry in China. While this strategy has had a near-term impact on our gross margin, we believe we will make it up through positive contributions to our market share, customer relationships and long term growth prospects."

    Third Quarter ResultsDuring the third quarter of 2013, the Company opened 32 new stores and closed 44 stores. As of September 30, 2013, the Company had 2,059 directly operated stores in total.  

    Revenue for the third quarter of 2013 increased by 7.7% to RMB683.2 million (US$111.6 million) from RMB634.6 million for the same period in 2012. Same store sales (for the 1,925 stores opened before December 31, 2011 and still operating) for the third quarter of 2013 increased by 10.5% compared with the same period in 2012. The increase in same store sales was primarily due to promotional initiatives aimed at increasing store traffic.

    Third quarter revenue contribution by product category was 23.1% from prescription drugs; 38.2% from over-the-counter ("OTC") drugs; 15.0% from nutritional supplements; 3.9% from herbal products; and 19.8% from convenience and other products.

    Third quarter gross profit was RMB289.6 million (US$47.3 million), a slight decrease from RMB293.0 million for the same period in 2012. Gross margin in the third quarter of 2013 was 42.4% compared with 46.2% for the same period of 2012. This decrease in gross margin was primarily the result of a more proactive marketing strategy on certain pharmaceutical products, nutritional supplements and convenience and other products.

    The Company's portfolio of private label products increased to 2,103 types of products as of September 30, 2013. Sales of private label products represented approximately 24.4% of the Company's revenue and 33.4% of gross profit for the third quarter of 2013.

    Sales, marketing and other operating expenses, as a percentage of revenue, in the third quarter of 2013, decreased to 38.3% from 40.1% in the same period of 2012. This decrease was primarily due to growth in same store sales and closure of underperforming stores.  

    General and administrative expenses as a percentage of revenue in the third quarter was 5.2%, compared with 5.0% for the same period in 2012. This increase was mainly due to RMB5.7 million (US$0.9 million) penalty imposed by Price Bureau of Yuexiu District in Guangzhou City of Guangdong Province on our subsidiary Guangzhou Nepstar for noncompliance with certain local government-guided pricing policies.

    During the third quarter, the company recognized an impairment loss of RMB 1.0 million, which represents the reduction of the carrying amount of the property and equipment of certain underperforming stores.

    Loss from operations in the third quarter of 2013 was RMB8.5 million (US$1.4 million), compared with income from operations of RMB4.2 million in the same period in 2012. The loss from operations in the third quarter of 2013 was mainly due to lower gross margin and the above mentioned RMB5.7 million (US$0.9 million) penalty.

    Interest income for the third quarter of 2013 was RMB3.9 million (US$0.6 million) compared with RMB3.6 million in the same period in 2012.

    Dividend income from cost method investments was RMB3.0 million (US$0.5 million) in the third quarter of 2013, compared with nil in the same period of 2012. On December 28, 2012, the Company completed the sale of its entire 40% equity interests in Yunnan Jianzhijia Chain Drugstore Ltd. for a total cash consideration of approximately RMB 81.5 million. Equity in income of an equity method investee was nil in the third quarter of 2013, compared with RMB0.3 million in the same period in 2012.

    Excluding the effect of the above mentioned penalty at RMB5.7 million (US$0.9 million) from loss before income tax expenses, which is not tax deductible, the Company's effective tax rate was 75.3% for the third quarter of 2013.  The Company's income tax expense was RMB 3.1 million (US$0.5 million) for the third quarter of 2013, compared with RMB6.3 million for the same period in 2012. As compared to the PRC statutory tax rate of 25% applicable to our major operating subsidiaries, the difference in the effective income tax rate for the current quarter was primarily due to non-deductible expenses and the relatively high amounts of operating losses from loss-making subsidiaries, for which full valuation allowances were made on their deferred tax assets, as compared to the overall results of the Company.

    Net loss for the third quarter of 2013 was RMB4.7 million (US$0.8 million), which represented RMB0.05 (US$0.008) basic and diluted loss per ADS. Net income for the third quarter of 2012 was RMB1.9 million, which represented RMB0.02 basic and diluted earnings per ADS.

    Net cash-flow from operating activities in the third quarter of 2013 was RMB10.6 million (US$1.7 million), compared with RMB0.05 million for the same period in 2012.

    As of September 30, 2013, the Company's total cash, cash equivalents, short-term and long-term bank deposits were RMB665.3 million (US$108.7 million) and its shareholders' equity was RMB1.0 billion (US$167.3 million), compared with total cash, cash equivalents, bank deposits and restricted cash of RMB664.4 million and shareholders' equity of RMB1.03 billion as of December 31, 2012.

    Business Outlook"Fourth quarter is important for us as winter is the high season for cold-cough medicines and nutritional supplements. We are working hard to maintain same store sales growth and per store transactions. Our focus remains on optimizing product mix and improving margins," Mr. Zhang concluded.

    Conference Call InformationThe Company will host a conference call, to be simultaneously webcasted, on Tuesday, November 26, 2013 at 8:00 a.m. Eastern Time / 9:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing +1-877-407-9210 (North America) or +1-201-689-8049 (International) approximately five minutes before the appointed starting time. A live web cast of the conference call will be available on the Nepstar website at

    A replay of the call will be available shortly after the conclusion of the conference call through December 3, 2013 at 11:59 p.m. Eastern Time. An archived Web cast of the conference call will be available on the Nepstar website at Interested parties may access the replay by dialing +1-877-660-6853 (North America) or +1-201-612-7415 (International) and entering conference ID number 13572581.

    About China Nepstar Chain Drugstore Ltd.China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is the largest retail drugstore chain in China based on the number of directly operated stores. As of September 30, 2013, the Company had 2,059 stores across 76 cities, one headquarter distribution center and 16 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmaceutical products and services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the continuing economic growth in China and to take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to

    Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    Exchange Rate InformationThe United States dollar (US$) amounts disclosed in this press release are presented solely for the convenience of the reader. Translations of amounts from RMB into United States dollars were calculated at the certified exchange rate of US$1.00 = RMB6.1200 on September 30,, 2013 as set forth in the H.10 weekly statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted into US$ at that rate on September 30, 2013, or at any other date. The percentages stated are calculated based on RMB amounts.

    Contacts:Zixin Shao
    China Nepstar Chain Drugstore Ltd.
    Chief Financial Officer

    Dixon Chen
    Investor Relations

    Ivette Almeida
    Media Relations

    Tables followChina Nepstar Chain Drugstore Ltd. Unaudited Condensed Consolidated Statements of Comprehensive Income/(Loss)(amounts in thousands – except per-share and per-ADS data)Three-month period endedSeptember 30,201220132013RMBRMBUSDRevenue



    111,627Cost of goods sold



    (64,300)Gross profit



    47,327Sales, marketing and other operating expenses



    (42,726)General and administrative expenses



    (5,811)Impairment losses of property and equipment



    (171)Income/(loss) from operations



    (1,381)Interest income



    636Dividend income from cost method investments



    490Equity in income of an equity method investee



    -Income/(loss) before income tax expense



    (255)Income tax expense



    (504)Net income/(loss) attributable to China Nepstar
    Chain Drugstore Ltd.



    (759)Earnings per ordinary share:Basic earnings/(losses) per ordinary share



    (0.004)Basic earnings/(losses) per ADS



    (0.008)Diluted earnings/(losses) per ordinary share



    (0.004)Diluted earnings/(losses) per ADS



    (0.008)Net income/(losses) attributable to China Nepstar
    Chain Drugstore Ltd.



    (759)Other comprehensive loss, net of tax:Foreign currency translation adjustments



    (14)Comprehensive income/(loss) attributable to
    China Nepstar Chain Drugstore Ltd.



    (773)China Nepstar Chain Drugstore Ltd.Unaudited Condensed Consolidated Balance Sheets(amounts in thousands) As ofAs ofAs ofDecember 31,September 30,September 30,201220132013RMBRMBUSDASSETSCurrent assetsCash and cash equivalents

    371,256334,56854,668Short-term bank time deposits

    237,100290,44047,458Restricted cash

    36,000--Accounts receivable, net of allowance for doubtful

    114,601130,90421,390Amounts due from related parties

    8,2544,777781Prepaid expenses, deposits and other current assets


    478,483489,50779,985Deferred tax assets

    1,7043,091505Total current assets

    1,394,6501,424,053232,689Non-current assetsLong-term bank time deposits

    20,00040,2566,578Property and equipment, net

    120,237116,52519,040Rental deposits

    38,23640,0996,551Cost method investments

    12,63812,6382,065Intangible assets, net


    51,81951,8198,467Deferred tax assets

    3,0569,9611,628Accrued interest income

    50729448Total non-current assets

    249,361274,10144,787Total assets1,644,0111,698,154277,476LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilitiesAccounts payable

    356,095399,67465,306Bills payable

    20,5342,328380Amounts due to related parties

    18,38126,8694,390Accrued expenses and other payables

    105,503123,90520,247Income tax payable

    40,96736,3815,945Deferred income

    14,32720,8713,410Total current liabilities

    555,807610,02899,678Non-current liabilitiesDeferred income

    18,36518,1132,960Deferred tax liabilities

    7,4997,6591,251Other non-current liabilities

    36,23738,4326,280Total non-current liabilities

    62,10164,20410,491Total liabilities617,908674,232110,169Shareholders' equityShare capital

    15815826Additional paid-in capital

    832,811832,811136,080Accumulated other comprehensive loss

    (41,688)(42,421)(6,932)Retained earnings

    234,822233,37438,133Total shareholders' equity

    1,026,1031,023,922167,307Total liabilities and shareholders' equity1,644,0111,698,154277,476

    SOURCE China Nepstar Chain Drugstore Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
    2. CentraState and Freehold Radiology Group train physicians from China
    3. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
    4. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
    5. China Biologic Products to Host Earnings Conference Call on May 9, 2012 at 8:00 a.m. EDT (NY)
    6. China Biologic Products Reports Higher Results for the First Quarter 2012
    7. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
    8. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
    9. China Botanic Attends 67th PHARMCHINA Fair
    10. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
    11. China Botanic Attends the 111th China Import and Export Fair
    Post Your Comments:
    (Date:10/9/2015)... 2015 Eli Lilly and Company (NYSE: LLY ... approximately 50 new jobs to its research and development presence ... York, New York . --> ... will include a translational immuno-oncology hub and a Lilly "portal," ... access to cutting-edge drug discovery capabilities, including chemistry and lead ...
    (Date:10/9/2015)... 2015 Ansun BioPharma announced a presentation at ... ) regarding the compassionate use of DAS181 under an ... who was co-infected with influenza and parainfluenza (Abstract # ... O 2 requirement was reduced and the patient,s ... go off the respirator on day 5. Between day ...
    (Date:10/9/2015)... El ,JCA-Mauvernay Award 2015, se ha otorgado a los ... Junko Takita    --> El ,JCA-Mauvernay Award 2015, ... y Junko Takita    --> ... a los doctores Yutaka Kondo y ... global con sede enSuiza, presentará el ,JCA-Mauvernay Award, el 10 de octubre a ...
    Breaking Medicine Technology:
    ... AstraZeneca (NYSE:,AZN) today announced that it submitted ... Food and Drug Administration (FDA) for approval of ... for the treatment of patients with Chronic Obstructive,Pulmonary ... long-term,maintenance treatment of asthma in patients 12 years ...
    ... Inc. ("QI"),announces the commencement of a Phase I/II ... a novel anti-cancer vaccine/immunotherapy that will,be used on ... accepted,into the study have previously failed to respond ... QI has commissioned,the study to be done by ...
    Cached Medicine Technology:
    (Date:10/10/2015)... ... ... have to walk with crutches for the rest of my life," said an inventor from ... that would give me more independence and freedom would be amazing. This inspired me to ... developed the STRAP IN to enable an individual to walk with crutches without having to ...
    (Date:10/10/2015)... ... , ... The Bank of America 500 NASCAR Sprint Cup Series race is ... defending race winner, Kevin Harvick, will battle it out for the checkered flag with ... the stars of the NASCAR Sprint Cup Series. As part of the opening ...
    (Date:10/10/2015)... ... October 10, 2015 , ... Attending medical school and ... men, women and children. Depending on the school, the exact details of the ... field. , Students in a medical school must complete undergraduate classwork and requirements ...
    (Date:10/10/2015)... PA (PRWEB) , ... October 10, 2015 , ... ... Wigrizer, Brecher & Miller is pleased to be recognized by The National Law ... This list acknowledges the 50 law firms across the United States who obtained ...
    (Date:10/9/2015)... ... October 09, 2015 , ... Doctors on Liens ... in Fresno , to provide highly needed medical care to personal injury victims. ... medical providers to diagnose, document and treat the variety of conditions ailing them. ...
    Breaking Medicine News(10 mins):
    ... Calif., Sept. 8 (Nasdaq: WHRTD ) - World ... the Company received a NASDAQ Staff Deficiency Letter indicating that the ... This rule requires the Company to maintain a minimum of 500,000 ... Subsequently on September 4, 2009, the Company received a letter from ...
    ... , WESTON, Fla., Sept. 8 Kidz-Med ... today announced the receipt of a follow-up purchase order of equal ... and closed a large purchase of Kidz-Med,s ... Company,s history. , , Dr. Christopher ...
    ... , Expanding facility will provide training ... the Highbridge area of the Bronx , , ... officially open the newest addition to the non-profit agency on September ... cutting ceremony at the facility. Located at 1438 Ogden Ave., ...
    ... NEW YORK, NY, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: ... company that identifies, acquires, and develops novel drug ... today announced it has appointed Dr. Anders Boegh ... Dr. Boegh Jensen will contribute his considerable expertise ...
    ... results for recipients in study , TUESDAY, Sept. 8 ... organ donors may help preserve the quality of their ... Most transplanted kidneys come from donors whose hearts are ... chain of events that can damage organs and increase ...
    ... Ohio Hairstylists may have a unique opportunity to ... according to a small, exploratory study. More than ... older clients often or always shared their problems during ... to notice when their older clients are starting to ...
    Cached Medicine News:
    ... ideal where space is restricted. Due to ... and flexible in every situation. For many ... be positioned optimally on the JUPITER during ... the operating theatre, the high level of ...
    ... schaerer axis 800 operating ... designed for those disciplines ... access. The stability, the ... the offset positioned telescoping ...
    ... words "mobile operating table" literally! The Alphastar 1132 ... of a general purpose operating table - is ... operations, a cable connected hand control, an IR-hand ... there is a control panel at the top ...
    ... introduce the Cmax operating table that combines ... surgical table with the radiolucence and precise ... the most advanced, versatile surgical table on ... to support advancements in surgical procedures and ...
    Medicine Products: